Loading...
•
Dec 31, 2024
Surmodics Q1 2025 Earnings Report
Surmodics' financial performance declined slightly year-over-year, with revenue decreasing by 2% and a net loss reported, impacted by lower SurVeil DCB revenue and merger-related charges, but offset by growth in medical device performance coatings royalties and sales of Pounce thrombectomy platforms.
Key Takeaways
Surmodics reported a slight decrease in total revenue, a net loss, and an adjusted EBITDA that was slightly less than the prior year. The revenue decrease was primarily due to lower SurVeil DCB revenue, offset by growth in other areas. The net loss was impacted by merger-related charges.
Total revenue decreased by 2% year-over-year to $29.9 million.
Excluding SurVeil DCB license fee revenue, total revenue decreased by 3% year-over-year to $28.7 million.
GAAP net loss was $(3.7) million, compared to $(0.8) million in the prior-year period.
Adjusted EBITDA was $3.6 million, compared to $3.9 million in the prior-year period.
Surmodics
Surmodics
Surmodics Revenue by Segment
Revenue by Segment
Medical Device Revenue
CapyFin.comIn Vitro Diagnostics Revenue
CapyFin.com Forward Guidance
Surmodics is not providing financial guidance for fiscal year 2025 due to the pending acquisition by GTCR.
Revenue & Expenses
Visualization of income flow from segment revenue to net income